Figures
- Fig. 1.—
Participants and responders of questionnaires in the Nord-Trøndelag Health Study (HUNT) and the Bronchial Obstruction in the Nord Trøndelag (BONT) study 1995–1997. #: 5% random sample of the total population; ¶: subjects reporting ever having had asthma or asthma-related symptoms during the last 12 months, or long-standing cough; +: subjects reporting ever having had asthma or asthma-related symptoms during the last 12 months.
- Fig. 2.—
Forced expiratory volume in one second (FEV1) in % predicted by age, among never-smokers exposed (▴) and not exposed (□) to passive smoke, and among ever-smokers (•) in a) males and b) females.
- Fig. 3.—
Age-adjusted forced expiratory volume in one second (FEV1) (□), forced vital capacity (FVC) (•) as % predicted and FEV1/FVC (♦) by pack-yrs in males (–) and females (═) in the total Bronchial Obstruction in the Nord Trøndelag study group (random sample 2,791 subjects and symptom group 8,150 subjects).
- Fig. 4.—
Proportion of subjects in the Bronchial Obstruction in the Nord Trøndelag study sample reporting respiratory symptoms by forced expiratory volume in one second (FEV1) % predicted in males (–) and females (═), adjusted by age and pack-yrs. □: wheeze or breathlessness; •: daily cough in periods; ♦: chronic bronchitis.
- Fig. 5.—
Forced expiratory volume in one second (FEV1) % predicted in males (–) and females (═), reporting no respiratory symptoms and respiratory symptoms with and without diagnosis of respiratory disease, by age. □: no respiratory symptoms; •: respiratory symptoms; ♦: respiratory symptoms and doctor diagnosed asthma or chronic bronchitis/emphysema.
- Fig. 6.—
Age and pack-yrs adjusted proportions (%) reporting “very well” or “well” to questioning on self-rated global health by forced expiratory volume in one second (FEV1) and sex, with 95% confidence intervals in the total Bronchial Obstruction in the Nord Trøndelag study sample. ▴: males; ♦: females.
Tables
- Table 1
Demographical data, lung function, smoke history, reported respiratory symptoms and global self-rated health (SRH), among participants in the Bronchial Obstruction in Nord-Trøndelag (BONT) study phase I random sample (5% random sample of the total population) and symptom group (those reporting ever having had asthma, ever use of asthma medications or attacks of wheezing or breathlessness during the last 12 months)
Characteristics 5% Random sample Symptom group# Females Males Females Males Number¶ 1510 (85.5) 1281 (83.7) 4254 (82.2) 3896 (79.4) Age yrs 49.6±16.5 50.1±16.1 50.1±17.1 51.5±17.0 Weight kg 70.8±12.5 83.7±12.4 72.7±14.2 84.4±13.7 Height cm 163.9±6.4 177.4±7.1 163.7±6.4 176.6±6.7 Body mass index kg·m−2 26.3±4.4 26.5±3.4 27.2±5.2 27.0±3.9 Lung function FEV1 L+ 2.80 (96.4) 3.82 (94.3) 2.56 (88.6) 3.40 (84.8) FVC L+ 3.44 (97.5) 4.85 (97.3) 3.25 (92.6) 4.52 (92.2) Smoking habit Never-smoker 50.7 41.1** 43.1 29.7** Exsmoker 18.9 29.3** 19.5 33.9** Current smoker 30.0 29.6 37.3 36.2 Pack-yrs in ever smokers§ 11.5±8.8 15.5±14.8** 12.9±9.9 17.9±15.6** Respiratory symptoms/diseases Attacks of wheezing or breathlessness during the last 12 months 13.7 13.9 73.0 73.3 Ever having had asthma 8.6 8.4 54.5 53.4 Ever having used asthma medication 8.1 7.9 53.3 46.6** Current asthma 5.6 4.6 33.8 30.9** Daily coughing in periods 15.3 17.6** 47.8 44.4** Cough with phlegm 8.4 10.2 27.9 28.7 Chronic bronchitis 3.2 5.1* 12.6 14.4* Global SRH Poor 1.5 1.6 3.3 4.2* Not so good 27.4 23.1* 44.8 39.9** Good 56.4 59.1 44.8 49.1** Very good 14.7 16.1 7.1 6.8 -
Data are presented as mean±sd or mean (%) unless otherwise stated
-
#: excluded those who reported symptoms in the 5% random sample
-
¶: (per cent of those invited to BONT phase I among participants at the main screening)
-
+: % predicted
-
§: adjusted by age. In each sample the difference by sex was tested by the Chi-squared test for proportions and variance analyses for mean number of pack-yrs
-
FEV1: forced expiratory flow in one second
-
FVC: forced vital capacity
-
SRH: self related health
-
*: p<0.05
-
**: p<0.01
-
